Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

Shots:Ahsan spoke about the US FDA acceptance for Priority Review of sBLAs for PADCEV and KEYTRUDA to treat patients with LA/mUC who are not eligible to receive cisplatin-containing CTHe also talked about the study design and outcomes from the P-Ib/II (EV-103) clinical trial that supported the sBLA. The results from Dose Escalation/Cohort A…

BySenior EditorAugust 17, 2023

THOUGHTSPOT

Social Media Listening in Pharmaceutical Industry

Shots:When it comes to embracing new-age technologies, the pharmaceutical industry always remains on the front foot. Galvanized by novel technological advances and innovations, the pharmaceutical industry is forging ahead at a momentous paceSocial media listening fosters the use of leveraging several social media platforms to gather insights, resolve queries, carry out online market…

BySaurabh ChaubeyAugust 8, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in June 2023

Shots:The US FDA approved 12 NDAs and 3 BLA in June 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 69 novel products in 2023In June 2023, the major highlights drugs were Talzenna + Xtandi approval for prostate cancer, Rystiggo for generalized myasthenia gravisPharmaShots…

BySenior EditorJuly 19, 2023

VIEWPOINTS

Andrea Mugan, Global Franchise Head of DDR & GYN/GU Cancers, AstraZeneca Shares Insights on ‘Never Miss’ campaign

Shots:Andrea briefed PharmaShots about the global prostate cancer awareness ‘Never Miss’ campaign developed by AstraZeneca and MSD to help men understand their potential risk of developing prostate cancerHe also talked about the increasing number of prostate cancer patients and how this campaign will help support those who may be impacted by prostate cancer…

BySenior EditorJune 22, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in August 2022

The EMA approved 5 New Chemical Entity (NCE) and 4 Biologic Drugs in August 2022, leading to treatments for patients and advances in the healthcare industryIn August 2022, the major highlights drugs were Lynparza’s approval for breast cancer, Imbruvica (ibrutinib) for chronic lymphocytic leukaemia, Sunlenca (lenacapavir) for HIV InfectionPharmaShots has compiled a list…

BySenior EditorSeptember 28, 2022

TOP 20

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology- cardiology- and neurology but are they…

ByPrince GiriJuly 17, 2020

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

Insights+: The US FDA New Drug Approvals in June 2023

Andrea Mugan, Global Franchise Head of DDR & GYN/GU Cancers, AstraZeneca Shares Insights on ‘Never Miss’ campaign

Insights+: EMA Marketing Authorization of New Drugs in August 2022

Top 20 Prescription Drugs Based on 2019 Revenue

Contact US

OUR INFORMATION

FOLLW US

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

Social Media Listening in Pharmaceutical Industry

Insights+: The US FDA New Drug Approvals in June 2023

Andrea Mugan, Global Franchise Head of DDR & GYN/GU Cancers, AstraZeneca Shares Insights on ‘Never Miss’ campaign

Insights+: EMA Marketing Authorization of New Drugs in August 2022

Top 20 Prescription Drugs Based on 2019 Revenue

FOLLW US

Sign Up to Our Newsletter